Measures Under the Act on Regenerative Medicine Safety
Overview
On July 31, 2026, the Ministry of Health, Labour and Welfare took administrative action against the administrators of two clinics in Chuo City, Tokyo, and Izumisano City, Osaka Prefecture, and a business operator in Izumisano City. It also requested corrective action from a business operator in Seoul, South Korea. The organizations concerned include entities that changed their names or trade names.
Key points
- The Ministry of Health, Labour and Welfare took administrative action and requested corrective action under the Act on the Safety of Regenerative Medicine.
- The organizations concerned were two clinics in Tokyo and Osaka Prefecture, one business operator in Osaka Prefecture, and one business operator in South Korea.
- Administrative action was taken against the administrators of the two clinics and the domestic business operator; a corrective action request was issued to the business operator in Seoul, South Korea.
Overview
The Ministry of Health, Labour and Welfare announced measures under the Act on the Safety of Regenerative Medicine on July 31, 2026. The measures concerned clinic administrators, a domestic business operator, and a business operator in South Korea.
The announcement detailed measures under Article 23, Paragraph 1; Article 48, Paragraph 2; and Article 48, Paragraph 2, as applied mutatis mutandis under Article 50, Paragraph 2 of the Act.
Details
Administrative action under Article 23, Paragraph 1 of the Act was taken against the administrators of Medical Corporation Neopolis Clinic Ginza Clinic (Chuo City, Tokyo) and Osaka Bethesda Clinic (Izumisano City, Osaka Prefecture). Osaka Bethesda Clinic changed its name on May 21, 2026; before the change, it was Medical Corporation Reishokai Trinity Clinic Osaka.
Administrative action under Article 48, Paragraph 2 of the Act was taken against American Angel Stem Co., Ltd. (Izumisano City, Osaka Prefecture). The company changed its trade name on July 1, 2026; before the change, it was JASC Co., Ltd.
A request for corrective action under Article 48, Paragraph 2, as applied mutatis mutandis under Article 50, Paragraph 2 of the Act, was issued to RBio Co. Ltd. (Seoul, South Korea). A Korean-language version of the press release was also provided.